Effect of maternal infections on antibody concentrations among infants at one year of age.

<p>Effect of maternal infections on antibody concentrations among infants at one year of age.</p

Subgroup analysis of the effect of randomised maternal treatment on antibody concentrations among infants at one year of age in groups according to maternal infection status.

<p>Subgroup analysis of the effect of randomised maternal treatment on antibody concentrations among infants at one year of age in groups according to maternal infection status.</p

Baseline characteristics of mothers whose children were enrolled into the study and provided samples at nine years of age.

<p>Baseline characteristics of mothers whose children were enrolled into the study and provided samples at nine years of age.</p

T-SPOT.TB assay results at five years and at follow-up: Protocol 1.

<p>T-SPOT.TB assay results at five years and at follow-up: Protocol 1.</p

T-SPOT.TB assay results at five years and at follow-up: Protocol 2.

<p>T-SPOT.TB assay results at five years and at follow-up: Protocol 2.</p

Assessment of size of TST in relation to T-SPOT.TB and TST results.

<p>IQR: interquartile range; + indicates positive result; – indicates negative result.</p

Association between RD1 antigens at five years and at follow-up.

<p>Results are presented as logs (to base 10) of spot forming units for the two RD1 antigens. (a) ESAT-6 at five years vs.CFP-10 at five years (n = 179); r_s = 0.7548 (b) ESAT-6 follow-up vs. CFP-10 follow-up (n = 158); r_s = 0.7838 (c) CFP-10 at five years vs. CFP-10 at follow-up (n = 127); r_s = 0.3125 (d) ESAT -6 at five years vs. ESAT-6 at follow-up (n = 163); r_s = 0.3576.</p

Median difference in spot counts to ESAT-6 and CFP-10 for participants whose T-SPOT.TB result varied between age five and follow-up.

<p>SFUs: spot forming units; IQR: interquartile range; + indicates positive result; – indicates negative result.</p

<i>Mycobacterium tuberculosis</i> infection prevalence estimates by different measures.

<p>The denominator is 907 for all the estimates.</p>*<p>All but 9 of the baseline T-SPOT.TB positives were followed up. Prevalence doesn’t change when the 9 are subtracted from the denominator.</p>**<p>Does not take into account the baseline T-SPOT.TB negatives that were not followed up, yet might have turned positive on follow-up. This is not likely to change the prevalence estimates, since most (96%) of the baseline negatives that were followed up remained negative.</p

Agreement between T-SPOT.TB and TST results.

<p>+ indicates positive result; – indicates negative result.</p